KIR2DL1

Across TCGA pan-cancer cohorts, KIR2DL1 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of KIR2DL1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where KIR2DL1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types KIR2DL1 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, LUAD, and LUSC are the cancer types where KIR2DL1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KIR2DL1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.444	<.001	11	view →
LUAD	All	III,IV	−0.623	<.001	9	view →
LUSC	Female	II,III,IV	−0.888	<.001	6	view →
HNSC	Male	III,IV	+0.099	.022	3	view →
BLCA	All	All	−0.040	.044	2	view →
LIHC	Male	All	−0.132	.011	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

KIR2DL1–KIRC

Open the KIRC breakdown →